Zai Lab Limited (ZLAB) is in Healthcare, Biotechnology, based in China, listed on NasdaqGM. Market cap 2.79B USD. 52-week range 15.96 to 32.76 USD. Data as of 2026-10-09.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for ...